Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma

医学 内科学 肿瘤科 淋巴瘤 外科 自体干细胞移植 临床试验 移植 前瞻性队列研究 完全响应 联合疗法 嵌合抗原受体 免疫疗法 化疗 细胞疗法 造血干细胞移植 临床研究阶段 胃肠病学 存活率 生存分析 干细胞
作者
Jiaqi Li,Shanglong Feng,Ying Zhang,Yuchen Hua,Liqing Kang,Lei Yu,Jia Chen,Xiebin Bao,Ting Xu,Depei Wu,Xiebing Bao,Depei Wu,Caixia Li
出处
期刊:Bone Marrow Transplantation [Springer Nature]
卷期号:146 (6): 1933-1933
标识
DOI:10.1038/s41409-026-02858-5
摘要

Abstract Objective:Given the poor prognosis of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), we compared the efficacy and safety of sequential CD19/CD22 chimeric antigen receptor T (CAR-T) cell therapy following autologous stem cell transplantation (ASCT) versus CAR-T monotherapy to identify more effective treatment strategies. Methods:We conducted a single-arm, prospective study to evaluate sequential CD19/CD22 CAR-T cell therapy following ASCT. Concurrently, patients who declined ASCT and received CD19/CD22 CAR-T monotherapy during the same period were included as a contemporaneous control cohort. Group allocation was based solely on patient preference, allowing for a comparative analysis of treatment efficacy and safety between the two approaches (NCT03196830). Results:Between February 2020 to August 2023, 50 patients were included in the final analysis, comprising 23 in the ASCT+CAR-T group and 27 in the CAR-T alone group. As of April 2025, the median follow-up duration was 28.4 months. In ASCT+CAR-T group, the complete response (CR) rate in the best response evaluation (17/23) was as high as 73.9% (95%CI 51.6%-89.8%). Moreover, the ASCT+CAR-T group demonstrated superior clinical outcomes when compared to CAR-T monotherapy. A total of 49 patients were response-evaluable. The best response results revealed a striking advantage for ASCT+CAR-T group, with adjusted CR rates of 76.7% (95%CI 56.2%-92.4%) versus 23.9% (95%CI 8.3%-42.0%) (p=0.003) and overall response rates (ORR) of 100% (95%CI 100%-100%) versus 61.9% (95%CI 39.5%-84.2%) compared to CAR-T monotherapy (p=0.001). In addition, these robust response benefits also translated into superior long-term outcomes, with significantly improved adjusted 2-year event-free survival (EFS) (50.7%, 95%CI 31.1%-70.3% vs 23.3%, 95%CI 6.4%-40.2%; p=0.014) and adjusted 2-year overall survival (OS) (72.2%, 95%CI 53.0-91.5% vs 33.9%, 95%CI 14.0-53.9%; p=0.008) in the ASCT+CAR-T group. These clinical benefits persisted in sensitivity analyses excluding patients with CNS involvement (n=45), with adjusted 2-year EFS 54.1% (95%CI 33.3%-74.9%) versus 24.5% (95%CI 7.3%-41.8%) in ASCT+CAR-T and CAR-T group, respectively (p=0.013), and 2-year OS 76.9% (95%CI 55.4%-98.3%) versus 35.0% (95%CI 18.4%-51.7%) , respectively (p=0.005). The most common adverse event (AE) in both groups was hematologic toxicity. All patients experienced grade ≥3 neutropenia, with significantly higher incidence of grade ≥3 thrombocytopenia (p=0.011) and a trend toward increased grade ≥3 anemia (p=0.056) in the ASCT+CAR-T group, which were attributed to the myeloablative conditioning regimen. Notably, all 23 patients in the ASCT+CAR-T group achieved successful hematopoietic reconstitution following transplantation. The median time to neutrophil and platelet engraftment was 9 days (range, 8-13) and 12 days (range, 9-30), respectively. The analysis revealed that the incidence of severe (grade ≥3) cytokine release syndrome (CRS) did not differ significantly between groups (13.0% vs 7.4%, p=0.651). Importantly, no fatal CRS events occurred in either group. The safety profile was further characterized by a single fatal immune effector cell-associated neurotoxicity syndrome (ICANS) case in the CAR-T group, which did not occur in the ASCT+CAR-T group. Conclusions: Sequential CD19/CD22 CAR-T cell therapy following ASCT represents a clinically significant advancement for R/R LBCL, demonstrating unprecedented survival outcomes with a manageable safety profile. This approach may serve as a potential new standard of care for eligible patients. Further validation through larger, multicenter randomized controlled trials with extended follow-up is warranted to confirm its long-term efficacy and safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
饲料批发的应助被川沧采纳,获得10
1秒前
姚序东完成签到,获得积分10
1秒前
2秒前
2秒前
3秒前
号左左发布了新的文献求助50
3秒前
九九发布了新的文献求助10
4秒前
5秒前
xing_xing的应助被曾经的剑身采纳,获得20
5秒前
超级无敌发布了新的文献求助10
5秒前
zzz发布了新的文献求助10
5秒前
yz1005完成签到,获得积分10
5秒前
Lucas的应助被胡萝卜卜采纳,获得10
5秒前
反证谁能想的到完成签到,获得积分10
6秒前
7秒前
研友_nongdalyl完成签到,获得积分10
7秒前
8秒前
9秒前
榴莲气泡水完成签到 ,获得积分10
11秒前
11秒前
今后的应助被DionysusR采纳,获得10
11秒前
YY关注了科研通微信公众号
11秒前
ttttttt发布了新的文献求助10
12秒前
13秒前
香蕉觅云的应助被rachel采纳,获得10
13秒前
promise发布了新的文献求助10
13秒前
盛小珊完成签到,获得积分10
14秒前
齐xia完成签到 ,获得积分10
15秒前
William_l_c发布了新的文献求助50
15秒前
ff发布了新的文献求助10
15秒前
Akim的应助被Libra采纳,获得10
15秒前
zhanglx66完成签到 ,获得积分10
16秒前
17秒前
WU哇哇完成签到,获得积分10
17秒前
18秒前
思源的应助被99采纳,获得10
18秒前
rui完成签到 ,获得积分10
20秒前
xyzlancet完成签到,获得积分10
20秒前
直率天德完成签到,获得积分10
20秒前
合适尔风完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191140
求助须知:如何正确求助?哪些是违规求助? 9578110
关于积分的说明 21856695
捐赠科研通 7790440
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560328
邀请新用户注册赠送积分活动 2483288